Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Unknown 1Terminated 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Influenza, Human 2Serology Analysis 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 37Cytarabine 27Methotrexate 22Dexamethasone 20Vincristine 19fludarabine 15Mercaptopurine 14Etoposide 14Radiotherapy 12Daunorubicin 12Asparaginase 12Doxorubicin 11Prednisolone 9Idarubicin 9Busulfan 8pegaspargase 7blinatumomab 7Peripheral Blood Stem Cell Transplantation 6Melphalan 6Immunotherapy, Adoptive 6Imatinib Mesylate 6Dasatinib 6fludarabine phosphate 5Prednisone 5Methylprednisolone 5Filgrastim 5Whole-Body Irradiation 4Thioguanine 4Rituximab 4N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Influenza Vaccines × Clear all
NCT04626765 2020-11-13

CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia

Hebei Senlang Biotechnology Inc., Ltd.

Phase EARLY_PHASE1 Unknown
50 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡